z-logo
open-access-imgOpen Access
Studies on Chemotherapeutic Potential of Hydroethanolic Leaf Extract of Aegle marmelos on Human Lung Cancer Cell Lines
Author(s) -
Naresh Kumar,
G. Sridevi,
Raja Selvaraj,
S. Preetha
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i64a35706
Subject(s) - lung cancer , cancer , a549 cell , medicine , traditional medicine , viability assay , wnt signaling pathway , cancer cell , cell culture , mtt assay , oncology , pharmacology , biology , biochemistry , genetics , gene
Background: Lung cancer, one of the world’s leading causes of cancer death. There is an improvement in mortality by screening of lung cancer by low dose computed tomography. Long time ago, lung cancer was a reportable disease which now became a commonest cause of death due to cancer. Discovery of medicine for various diseases is still an ongoing process. A lot of diseases are still remaining a threat without any treatment or medicine. Herbal derived medicines are preferred because of their low side effects on patients. Objective: To investigate the role of Aegle marmelos against human lung cancer cell lines (A549 cell line). Materials and Methods: A549 cell lines were procured from NCCS (National center for cell sciences) Pune, India. It was cultured and viability of the cells before and after adding the extract was analysed using the MTT assay. mRNA amplification was done using real time PCR.Statistical analysis was done using ANOVA and dunken’s multiple test. Corresponding graphs are also plotted. Results: The viability of the cells decreased from 100% to 50%. The mRNA expression of wnt and β-catenin decreased after the addition of the extract. Conclusion: The study concluded that Aegle marmelos possesses a good, novel, innovative, anti- cancer activity against the lung cancer cell lines A549.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here